S2200
|
SWOG
|
A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2205
|
SWOG
|
Ice Compress: Randomized Trial Of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression For The Prevention Of Taxane-Induced Peripheral Neuropathy
|
Cancer Prevention and Control CIRB
|
Available to Open
|
|
S2206
|
SWOG
|
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2207
|
SWOG
|
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2209
|
SWOG
|
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2210
|
SWOG
|
A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer with Germline BRCA1/2 Mutations
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2212
|
SWOG
|
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2213
|
SWOG
|
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2302
|
SWOG
|
Pragmatica - Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care (SOC) for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
S2303
|
SWOG
|
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|